AAPL342.37-1.80 (-0.52%) ▼|ABBV291.31+3.07 (+1.07%) ▲|ABT109.93-3.67 (-3.23%) ▼|ACN260.50-4.66 (-1.76%) ▼|ADBE239.30-7.14 (-2.90%) ▼|AMAT332.72+13.47 (+4.22%) ▲|AMD449.04+44.64 (+11.04%) ▲|AMGN460.42+0.14 (+0.03%) ▲|AMT188.79-5.20 (-2.68%) ▼|AMZN259.30-0.91 (-0.35%) ▼|AVGO293.69+2.16 (+0.74%) ▲|AXP320.99-3.98 (-1.22%) ▼|BA173.40+0.90 (+0.52%) ▲|BAC49.42-0.34 (-0.68%) ▼|BKNG160.67-8.06 (-4.77%) ▼|BLK1,178.87+8.20 (+0.70%) ▲|BMY62.14-0.99 (-1.57%) ▼|BNY147.72+0.23 (+0.16%) ▲|BRK-B570.89-1.44 (-0.25%) ▼|C119.05+0.60 (+0.51%) ▲|CAT558.63+4.99 (+0.90%) ▲|CL96.56-2.13 (-2.16%) ▼|CMCSA24.39-0.56 (-2.24%) ▼|COF201.87-1.97 (-0.97%) ▼|COP136.27+0.81 (+0.60%) ▲|COST1,053.56-12.03 (-1.13%) ▼|CRM213.65-8.76 (-3.94%) ▼|CSCO93.85-1.87 (-1.95%) ▼|CVS83.85+2.52 (+3.10%) ▲|CVX212.61-0.32 (-0.15%) ▼|DE671.65+8.34 (+1.26%) ▲|DHR230.25+3.91 (+1.73%) ▲|DIS116.75-0.47 (-0.40%) ▼|DUK127.78-2.30 (-1.77%) ▼|EMR162.35-0.26 (-0.16%) ▼|FDX308.14-8.66 (-2.73%) ▼|GD354.06-2.29 (-0.64%) ▼|GE323.24+8.51 (+2.70%) ▲|GEV774.11+3.60 (+0.47%) ▲|GILD166.89-0.68 (-0.41%) ▼|GM86.16-3.17 (-3.55%) ▼|GOOG283.93+2.19 (+0.78%) ▲|GOOGL284.78+2.21 (+0.78%) ▲|GS865.82-3.13 (-0.36%) ▼|HD343.47-6.47 (-1.85%) ▼|HON220.05+4.27 (+1.98%) ▲|IBM245.00-2.11 (-0.85%) ▼|INTC56.28+4.03 (+7.71%) ▲|INTU341.50-13.34 (-3.76%) ▼|ISRG452.80-15.72 (-3.36%) ▼|JNJ276.22+3.90 (+1.43%) ▲|JPM334.49-2.85 (-0.84%) ▼|KO95.67-0.06 (-0.06%) ▼|LIN515.25-5.98 (-1.15%) ▼|LLY1,354.00-10.73 (-0.79%) ▼|LMT567.08-9.08 (-1.58%) ▼|LOW224.55-2.69 (-1.18%) ▼|LRCX200.44+15.24 (+8.23%) ▲|MA652.70-3.22 (-0.49%) ▼|MCD276.52-1.52 (-0.55%) ▼|MDLZ66.02-0.80 (-1.20%) ▼|MDT101.80-3.04 (-2.90%) ▼|META610.15+5.07 (+0.84%) ▲|MMM185.15-2.62 (-1.40%) ▼|MO76.12-1.46 (-1.88%) ▼|MRK146.73-0.21 (-0.14%) ▼|MS181.44-1.00 (-0.55%) ▼|MSFT530.61-5.32 (-0.99%) ▼|MU690.00+33.61 (+5.12%) ▲|NEE86.95-1.30 (-1.47%) ▼|NFLX63.41-2.15 (-3.28%) ▼|NKE38.59-0.97 (-2.45%) ▼|NOW101.97-0.39 (-0.38%) ▼|NVDA186.64+5.04 (+2.78%) ▲|ORCL116.10+0.94 (+0.82%) ▲|PEP141.34-1.37 (-0.96%) ▼|PFE29.39-0.06 (-0.20%) ▼|PG165.40-1.70 (-1.02%) ▼|PLTR160.38+5.39 (+3.48%) ▲|PM197.88-3.62 (-1.80%) ▼|QCOM165.41+8.66 (+5.52%) ▲|RTX189.53-2.35 (-1.22%) ▼|SBUX105.41-0.75 (-0.71%) ▼|SCHW91.49-1.09 (-1.18%) ▼|SO92.34-1.00 (-1.07%) ▼|SPG228.42+1.87 (+0.83%) ▲|T21.63-0.19 (-0.87%) ▼|TMO694.76+17.82 (+2.63%) ▲|TMUS162.01+1.42 (+0.88%) ▲|TSLA358.22+14.53 (+4.23%) ▲|TXN277.36-0.79 (-0.28%) ▼|UBER68.59-0.19 (-0.28%) ▼|UNH394.15-1.57 (-0.40%) ▼|UNP290.16-7.79 (-2.61%) ▼|UPS108.30-2.74 (-2.47%) ▼|USB59.45-0.30 (-0.50%) ▼|V422.65+0.06 (+0.01%) ▲|VZ45.69-0.43 (-0.93%) ▼|WFC83.94-0.36 (-0.43%) ▼|WMT125.52-2.20 (-1.72%) ▼|XOM165.87+0.57 (+0.34%) ▲|AAPL342.37-1.80 (-0.52%) ▼|ABBV291.31+3.07 (+1.07%) ▲|ABT109.93-3.67 (-3.23%) ▼|ACN260.50-4.66 (-1.76%) ▼|ADBE239.30-7.14 (-2.90%) ▼|AMAT332.72+13.47 (+4.22%) ▲|AMD449.04+44.64 (+11.04%) ▲|AMGN460.42+0.14 (+0.03%) ▲|AMT188.79-5.20 (-2.68%) ▼|AMZN259.30-0.91 (-0.35%) ▼|AVGO293.69+2.16 (+0.74%) ▲|AXP320.99-3.98 (-1.22%) ▼|BA173.40+0.90 (+0.52%) ▲|BAC49.42-0.34 (-0.68%) ▼|BKNG160.67-8.06 (-4.77%) ▼|BLK1,178.87+8.20 (+0.70%) ▲|BMY62.14-0.99 (-1.57%) ▼|BNY147.72+0.23 (+0.16%) ▲|BRK-B570.89-1.44 (-0.25%) ▼|C119.05+0.60 (+0.51%) ▲|CAT558.63+4.99 (+0.90%) ▲|CL96.56-2.13 (-2.16%) ▼|CMCSA24.39-0.56 (-2.24%) ▼|COF201.87-1.97 (-0.97%) ▼|COP136.27+0.81 (+0.60%) ▲|COST1,053.56-12.03 (-1.13%) ▼|CRM213.65-8.76 (-3.94%) ▼|CSCO93.85-1.87 (-1.95%) ▼|CVS83.85+2.52 (+3.10%) ▲|CVX212.61-0.32 (-0.15%) ▼|DE671.65+8.34 (+1.26%) ▲|DHR230.25+3.91 (+1.73%) ▲|DIS116.75-0.47 (-0.40%) ▼|DUK127.78-2.30 (-1.77%) ▼|EMR162.35-0.26 (-0.16%) ▼|FDX308.14-8.66 (-2.73%) ▼|GD354.06-2.29 (-0.64%) ▼|GE323.24+8.51 (+2.70%) ▲|GEV774.11+3.60 (+0.47%) ▲|GILD166.89-0.68 (-0.41%) ▼|GM86.16-3.17 (-3.55%) ▼|GOOG283.93+2.19 (+0.78%) ▲|GOOGL284.78+2.21 (+0.78%) ▲|GS865.82-3.13 (-0.36%) ▼|HD343.47-6.47 (-1.85%) ▼|HON220.05+4.27 (+1.98%) ▲|IBM245.00-2.11 (-0.85%) ▼|INTC56.28+4.03 (+7.71%) ▲|INTU341.50-13.34 (-3.76%) ▼|ISRG452.80-15.72 (-3.36%) ▼|JNJ276.22+3.90 (+1.43%) ▲|JPM334.49-2.85 (-0.84%) ▼|KO95.67-0.06 (-0.06%) ▼|LIN515.25-5.98 (-1.15%) ▼|LLY1,354.00-10.73 (-0.79%) ▼|LMT567.08-9.08 (-1.58%) ▼|LOW224.55-2.69 (-1.18%) ▼|LRCX200.44+15.24 (+8.23%) ▲|MA652.70-3.22 (-0.49%) ▼|MCD276.52-1.52 (-0.55%) ▼|MDLZ66.02-0.80 (-1.20%) ▼|MDT101.80-3.04 (-2.90%) ▼|META610.15+5.07 (+0.84%) ▲|MMM185.15-2.62 (-1.40%) ▼|MO76.12-1.46 (-1.88%) ▼|MRK146.73-0.21 (-0.14%) ▼|MS181.44-1.00 (-0.55%) ▼|MSFT530.61-5.32 (-0.99%) ▼|MU690.00+33.61 (+5.12%) ▲|NEE86.95-1.30 (-1.47%) ▼|NFLX63.41-2.15 (-3.28%) ▼|NKE38.59-0.97 (-2.45%) ▼|NOW101.97-0.39 (-0.38%) ▼|NVDA186.64+5.04 (+2.78%) ▲|ORCL116.10+0.94 (+0.82%) ▲|PEP141.34-1.37 (-0.96%) ▼|PFE29.39-0.06 (-0.20%) ▼|PG165.40-1.70 (-1.02%) ▼|PLTR160.38+5.39 (+3.48%) ▲|PM197.88-3.62 (-1.80%) ▼|QCOM165.41+8.66 (+5.52%) ▲|RTX189.53-2.35 (-1.22%) ▼|SBUX105.41-0.75 (-0.71%) ▼|SCHW91.49-1.09 (-1.18%) ▼|SO92.34-1.00 (-1.07%) ▼|SPG228.42+1.87 (+0.83%) ▲|T21.63-0.19 (-0.87%) ▼|TMO694.76+17.82 (+2.63%) ▲|TMUS162.01+1.42 (+0.88%) ▲|TSLA358.22+14.53 (+4.23%) ▲|TXN277.36-0.79 (-0.28%) ▼|UBER68.59-0.19 (-0.28%) ▼|UNH394.15-1.57 (-0.40%) ▼|UNP290.16-7.79 (-2.61%) ▼|UPS108.30-2.74 (-2.47%) ▼|USB59.45-0.30 (-0.50%) ▼|V422.65+0.06 (+0.01%) ▲|VZ45.69-0.43 (-0.93%) ▼|WFC83.94-0.36 (-0.43%) ▼|WMT125.52-2.20 (-1.72%) ▼|XOM165.87+0.57 (+0.34%) ▲|
12.8 C
New York
Monday, November 9, 2026

Tag: form

newsFORsourcecompanycontentinformationreleases1market

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant...

EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe jamais présentée

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results

ALMATY, Kazakhstan, June 15, 2025 /PRNewswire/ -- Freedom Holding Corp. (NASDAQ: FRHC), the diversified financial group with operations spanning 22 countries, today reported financial...

IBTA 最終截止日期：享譽全球的律師事務所 ROSEN 鼓勵損失超過 10 萬美元的 Ibotta, Inc. 投資者在該事務所對 IBTA 首次提出證券集體訴訟之重要截止日期 6 月 16 日前聘請律師

紐約, June 15, 2025 (GLOBE NEWSWIRE) --

事因：全球投資者權益律師事務所 Rosen Law Firm 提醒：(1) 根據及／或可追溯至因 Ibotta, Inc.（NYSE: IBTA）於 2024 年 4 月 18 日進行首次公開招股（簡稱「IPO」）所發行之註冊聲明及相關招股章程（統稱「註冊聲明」）而購買該公司證券之人士；或 (2) 於 2024 年 4 月 18 日至 2025 年 2 月 26 日期間（包括首尾兩日，簡稱「集體訴訟期」）購買該公司證券之人士注意，該事務所首次提出證券集體訴訟之重要首席原告截止日期為 2025 年 6 月 16 日。

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Backblaze Investor News: If You Have Suffered Losses in Backblaze, Inc. (NASDAQ: BLZE), You Are Encouraged to Contact The Rosen Law Firm About Your...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Backblaze, Inc. (NASDAQ: BLZE) resulting from allegations that Backblaze may have issued materially misleading business information to the investing public.

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

Eve Air Mobility Twenty-Year Market Outlook Highlights Growth of Urban Air Mobility Globally

Outlook highlights a $280 billion passenger revenue and 30,000 aircraft opportunities driven by urban population growth, traffic concerns, and a commitment to sustainability. PARIS,...

Prix Fitzgerald 2025 Laureate Announced at Hôtel Belles Rives

Renowned American Author Richard Ford Receives 14th Annual Literary Award for Be Mine 
Renowned American Author Richard Ford Receives 14th Annual Literary Award for Be Mine

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsForm

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers